Cargando…

Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics

Manganese-based nanomaterials (Mn-nanomaterials) hold immense potential in cancer diagnosis and therapies. However, most Mn-nanomaterials are limited by the low sensitivity and low efficiency toward mild weak acidity (pH 6.4–6.8) of the tumor microenvironment, resulting in unsatisfactory therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Guoqiang, Liu, Huiyi, Xu, Juntao, Zhang, Qingpeng, Dong, Zhe, Lei, Lingling, Zhang, Cheng, Yue, Renye, Gao, Hongchang, Song, Guosheng, Shen, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657629/
https://www.ncbi.nlm.nih.gov/pubmed/37980476
http://dx.doi.org/10.1186/s12951-023-02172-y
_version_ 1785148182373597184
author Guan, Guoqiang
Liu, Huiyi
Xu, Juntao
Zhang, Qingpeng
Dong, Zhe
Lei, Lingling
Zhang, Cheng
Yue, Renye
Gao, Hongchang
Song, Guosheng
Shen, Xian
author_facet Guan, Guoqiang
Liu, Huiyi
Xu, Juntao
Zhang, Qingpeng
Dong, Zhe
Lei, Lingling
Zhang, Cheng
Yue, Renye
Gao, Hongchang
Song, Guosheng
Shen, Xian
author_sort Guan, Guoqiang
collection PubMed
description Manganese-based nanomaterials (Mn-nanomaterials) hold immense potential in cancer diagnosis and therapies. However, most Mn-nanomaterials are limited by the low sensitivity and low efficiency toward mild weak acidity (pH 6.4–6.8) of the tumor microenvironment, resulting in unsatisfactory therapeutic effect and poor magnetic resonance imaging (MRI) performance. This study introduces pH-ultrasensitive PtMn nanoparticles as a novel platform for enhanced ferroptosis-based cancer theranostics. The PtMn nanoparticles were synthesized with different diameters from 5.3 to 2.7 nm with size-dominant catalytic activity and magnetic relaxation, and modified with an acidity-responsive polymer to create pH-sensitive agents. Importantly, R-PtMn-1 (3 nm core) presents “turn-on” oxidase-like activity, affording a significant enhancement ratio (pH 6.0/pH 7.4) in catalytic activity (6.7 folds), compared with R-PtMn-2 (4.2 nm core, 3.7 folds) or R-PtMn-3 (5.3 nm core, 2.1 folds), respectively. Moreover, R-PtMn-1 exhibits dual-mode contrast in high-field MRI. R-PtMn-1 possesses a good enhancement ratio (pH 6.4/pH 7.4) that is 3 or 3.2 folds for T(1)- or T(2)-MRI, respectively, which is higher than that of R-PtMn-2 (1.4 or 1.5 folds) or R-PtMn-3 (1.1 or 1.2 folds). Moreover, their pH-ultrasensitivity enabled activation specifically within the tumor microenvironment, avoiding off-target toxicity in normal tissues during delivery. In vitro studies demonstrated elevated intracellular reactive oxygen species production, lipid peroxidation, mitochondrial membrane potential changes, malondialdehyde content, and glutathione depletion, leading to enhanced ferroptosis in cancer cells. Meanwhile, normal cells remained unaffected by the nanoparticles. Overall, the pH-ultrasensitive PtMn nanoparticles offer a promising strategy for accurate cancer diagnosis and ferroptosis-based therapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-02172-y.
format Online
Article
Text
id pubmed-10657629
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106576292023-11-18 Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics Guan, Guoqiang Liu, Huiyi Xu, Juntao Zhang, Qingpeng Dong, Zhe Lei, Lingling Zhang, Cheng Yue, Renye Gao, Hongchang Song, Guosheng Shen, Xian J Nanobiotechnology Research Manganese-based nanomaterials (Mn-nanomaterials) hold immense potential in cancer diagnosis and therapies. However, most Mn-nanomaterials are limited by the low sensitivity and low efficiency toward mild weak acidity (pH 6.4–6.8) of the tumor microenvironment, resulting in unsatisfactory therapeutic effect and poor magnetic resonance imaging (MRI) performance. This study introduces pH-ultrasensitive PtMn nanoparticles as a novel platform for enhanced ferroptosis-based cancer theranostics. The PtMn nanoparticles were synthesized with different diameters from 5.3 to 2.7 nm with size-dominant catalytic activity and magnetic relaxation, and modified with an acidity-responsive polymer to create pH-sensitive agents. Importantly, R-PtMn-1 (3 nm core) presents “turn-on” oxidase-like activity, affording a significant enhancement ratio (pH 6.0/pH 7.4) in catalytic activity (6.7 folds), compared with R-PtMn-2 (4.2 nm core, 3.7 folds) or R-PtMn-3 (5.3 nm core, 2.1 folds), respectively. Moreover, R-PtMn-1 exhibits dual-mode contrast in high-field MRI. R-PtMn-1 possesses a good enhancement ratio (pH 6.4/pH 7.4) that is 3 or 3.2 folds for T(1)- or T(2)-MRI, respectively, which is higher than that of R-PtMn-2 (1.4 or 1.5 folds) or R-PtMn-3 (1.1 or 1.2 folds). Moreover, their pH-ultrasensitivity enabled activation specifically within the tumor microenvironment, avoiding off-target toxicity in normal tissues during delivery. In vitro studies demonstrated elevated intracellular reactive oxygen species production, lipid peroxidation, mitochondrial membrane potential changes, malondialdehyde content, and glutathione depletion, leading to enhanced ferroptosis in cancer cells. Meanwhile, normal cells remained unaffected by the nanoparticles. Overall, the pH-ultrasensitive PtMn nanoparticles offer a promising strategy for accurate cancer diagnosis and ferroptosis-based therapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-02172-y. BioMed Central 2023-11-18 /pmc/articles/PMC10657629/ /pubmed/37980476 http://dx.doi.org/10.1186/s12951-023-02172-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Guan, Guoqiang
Liu, Huiyi
Xu, Juntao
Zhang, Qingpeng
Dong, Zhe
Lei, Lingling
Zhang, Cheng
Yue, Renye
Gao, Hongchang
Song, Guosheng
Shen, Xian
Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title_full Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title_fullStr Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title_full_unstemmed Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title_short Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
title_sort ultrasmall ptmn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657629/
https://www.ncbi.nlm.nih.gov/pubmed/37980476
http://dx.doi.org/10.1186/s12951-023-02172-y
work_keys_str_mv AT guanguoqiang ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT liuhuiyi ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT xujuntao ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT zhangqingpeng ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT dongzhe ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT leilingling ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT zhangcheng ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT yuerenye ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT gaohongchang ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT songguosheng ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics
AT shenxian ultrasmallptmnnanoparticlesassensitivemanganesereleasemodulatorforspecificitycancertheranostics